Press Release Jet has a new domain  PRDistribution.com. We will redirect you to the in 5 seconds.

Klogene and Kogenix announce merger

keyboard_arrow_left   Back to News

  BOSTON, MA - 12/20/2017 (PRESS RELEASE JET)


Klogene Therapeutics, Inc. and Kogenix Therapeutics, Inc. today announced the merger of the two companies. The combined company, using the name Klogene, is focused on Klotho, a naturally occurring pleiotropic human protein that has been shown to have potential therapeutic effects in neurodegenerative diseases such as Alzheimer’s as well as kidney disease, certain cancers, and more. Higher levels of Klotho are associated with longevity and improved cognitive functions. 

“Klogene has skills, programs and intellectual property applicable to several strategies for increasing levels of Klotho – small molecules, gene therapy, gene editing technology CRISPR, and biologics,” said Menachem Abraham, Founder, Chairman and CEO. “We assembled a world class founding team and have access to world-renown scientific advisors (see www.klogene.com),” he added

The company, headquartered in Boston, has signed a number of research agreements with academic institutions and a small biotech firm. “We have active collaborations, including pre-clinical studies in disease models, in Europe, Israel and the United States” explained Abraham. “In addition to our own lab, on the Boston University School of Medicine campus, we make extensive use of contract research organizations, leading academic laboratories in our field, as well as other focused biotech startups.” 

“We are pleased to be Klogene’s provider of adeno-associated viral vectors,” said Dr. Miguel Chillon, Director of the Viral Vector Production Unit at Universitat Autonoma de Barcelona. “Our laboratory specializes in cloning, production and purification of adenovirus and adeno-associated virus serotypes for private companies and academic institutions”. Dr. Chillon is also a co-founder of Klogene.

Klogene has raised its seed capital from private investors and received a $1,490,000 National Institute of Health / National Institute on Aging (NIH/NIA) Small Business Innovation Research grant (SBIR).

About Klogene Therapeutics, Inc.

Klogene is developing therapies, based on increasing the level of anti-aging multifunctional protein Klotho, for neurodegenerative diseases, kidney disease, cancer and more.

Media Contact: 1-781-718-5102 mabraham@klogene.com 

Related Links:

https://www.nature.com/mp/journal/vaop/ncurrent/full/mp2017211a.html

https://www.newswire.com/news/kogenix-licenses-gene-therapy-for-prevention-of-age-related-dementia-20024631

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4960479/

Source: 

Klogene Therapeutics, Inc.

Media Contacts:

person_outline  Full Name:Menachem Abraham
phone  Phone Number:7817185102
business_center  Company:Klogene Therapeutics, Inc.
language  Website:www.klogene.com
mail_outline  
View Results in Google
Promote Your Business keyboard_arrow_right
PR Distribution